Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease-Reference-Cited by-同舟云学术

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

Published:2017-09 Issue:1 Volume:4 Page:e000212
ISSN:2052-4439
Container-title:BMJ Open Respiratory Research
language:en
Short-container-title:BMJ Open Resp Res

Author:

Flaherty Kevin R,Brown Kevin K,Wells Athol U,Clerisme-Beaty Emmanuelle,Collard Harold R,Cottin Vincent,Devaraj Anand,Inoue Yoshikazu,Le Maulf Florence,Richeldi Luca,Schmidt Hendrik,Walsh Simon,Mezzanotte William,Schlenker-Herceg Rozsa

Funder

Boehringer Ingelheim

Publisher

BMJ

Subject

Pulmonary and Respiratory Medicine

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world multicentre observational study protocol to assess the efficacy, safety and acceptability of a home monitoring programme for patients with interstitial lung disease (Preprint);2024-08-14

2. Serum stratifin measurement is useful for evaluating disease severity and outcomes in patients with acute exacerbation of interstitial lung disease: a retrospective study;BMC Pulmonary Medicine;2024-07-29

3. Assessment of Probability of Pulmonary Fibrosis Progression in Patients with Interstitial Lung Diseases to Determine Further Treatment Tactics;Tuberculosis and Lung Diseases;2024-07-04

4. The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial;Respiratory Investigation;2024-07

5. Effect of breathing exercises on patients with interstitial lung disease: A systematic review and meta-analysis;Quality of Life Research;2024-06-22